Raphael Pharmaceutical Inc.
No SEC Form 4 filings for $RAPH in the last 30 days.
See all $RAPH insider activity →Raphael Pharmaceutical Inc. (RAPH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 30, 2026, Raphael Pharmaceutical Inc. (the “Company”) entered into an Enterprise AI Transformation and Growth Partnership with AIcreatesAI Inc. (“AIcreatesAI”) pursuant to an Annual Managed Services Proposal and Agreem
Raphael Pharmaceutical Inc. (RAPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001415397 0001415397 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report
Over the past 7 days, alphai's AI scored 1 news story mentioning RAPH (Raphael Pharmaceutical Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
The agreement may boost operational efficiency but adds modest cash outflow; share‑based payment could dilute existing shareholders.
Board and C-suite turnover increases near-term execution and governance risk, but the filing does not provide financial guidance or operational details.
alphai scores every news story that mentions RAPH with an AI model for sentiment and relevance, and aggregates insider trades from Raphael Pharmaceutical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Raphael Pharmaceutical Inc. (RAPH) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On July 30, 2026, Raphael Pharmaceutical Inc. (the “Company”) entered into an Enterprise AI Transformation and Growth Partnership with AIcreatesAI Inc. (“AIcreatesAI”) pursuant to an Annual Managed Services Proposal and Agreem
1 min readRaphael Pharmaceutical Inc. (RAPH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001415397 0001415397 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report
2 min read